The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib

The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib

Non-small-cell lung cancer (NSCLC) represents a predominant histological subtype of lung cancer, characterized by high incidence and mortality rates. Despite significant advancements in therapeutic strategies and a deeper understanding of targeted therapies in recent years, tumor resistance remains...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Zhang, Zequn Wang, Xihua Wei, Mengyuan Han, Ribai Yan, Lijie Ma, Yan Pan
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Current Research in Pharmacology and Drug Discovery
Subjects:
Sphingosine kinase 1
Sphingosine-1-phosphate
Sphingosine 1-phosphate receptor
Gefitinib
Non-small-cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2590257124000397
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items